The experimental drug lecanemab shows "potential" as an Alzheimer s disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with
Experimental drug appears to slow progression of Alzheimer's disease. Here's what to know kcra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kcra.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company s.
acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.